Rabies vaccine - Biologic Drug Details

Summary for rabies vaccine

Tradenames:	2
High Confidence Patents:	0
Applicants:	3
BLAs:	3
Suppliers: see list	2
Recent Clinical Trials:	See clinical trials for rabies vaccine

Recent Clinical Trials for rabies vaccine

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Changchun BCHT Biotechnology Co.	PHASE1
Tsinghua University	NA
Second Affiliated Hospital of Bengbu Medical College	NA

See all rabies vaccine clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for rabies vaccine Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for rabies vaccine Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for rabies vaccine Derived from Patent Text Search

No patents found based on company disclosures

Rabies Vaccine: Market Dynamics and Financial Trajectory

Last updated: February 16, 2026

Market Overview and Growth Drivers

The global rabies vaccine market was valued at approximately $400 million in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 6% from 2023 to 2030. The growth is driven by increasing awareness of rabies prevention, expanding immunization campaigns, and rising dog population control programs in developing regions.

Key Market Segments

• Pre-exposure prophylaxis (PrEP): Accounts for 45% of the market. Growing demand in travelers and high-risk occupational groups.
• Post-exposure prophylaxis (PEP): Constitutes 55% of revenue. The primary driver owing to its urgent requirement after suspected exposure.

Regional Market Breakdown

Region	Share of Market (2022)	Growth Rate (2023-2030)	Key Factors
North America	35%	4%	High awareness, vaccination coverage, regulatory approval
Europe	25%	5%	Established vaccination programs, stable demand
Asia-Pacific	25%	8%	Rapid urbanization, pet population growth, emerging healthcare infrastructure
Latin America	10%	7%	Expanding public health initiatives
Africa	5%	10%	Increasing rabies cases, evolving health policies

Key Actors and R&D Pipeline

Major players include Pfizer with their Rabies Vaccine (RabAvert), GSK, Merck, and newer entrants from China and India. Pfizer controls around 50% of the market, holding a dominant position through established global distribution channels and regulatory approvals.

The R&D pipeline contains 5-6 upcoming formulations focused on innovative approaches such as recombinant viral vectors and adjuvant-enhanced vaccines. These aim to improve immunogenicity, reduce dosing frequency, and lower costs.

Regulatory and Policy Environment

• WHO Guidelines: Emphasize vaccination in bite-prone regions and aim to standardize PEP protocols.
• National Immunization Policies: Variations exist; higher adoption rates in developed countries, emerging in developing nations.
• Vaccine Licenses: Over 10 licensed rabies vaccines globally, with regulatory approval timelines ranging from 6 to 18 months depending on the region.

Financial Trajectory and Pricing

• Pricing: Ranged from $15 to $50 per dose, depending on the formulation, region, and procurement volume.
• Revenue Trends: Expected to increase due to higher vaccination rates and expanding coverage, especially in bulk procurement for public health campaigns.
• Cost Structure: Manufacturing costs are approximately $5-$10 per dose, with significant investments in R&D, regulatory approvals, and distribution logistics.

Challenges Impacting Market Growth

• Limitations in vaccine affordability in low-income regions.
• Logistics and cold chain requirements, especially for multi-dose regimens.
• Vaccine hesitancy and lack of awareness in certain regions.
• Limited R&D progress in developing single-dose or thermostable vaccines.

Investment Opportunities and Forecast

The forecast anticipates global revenues reaching approximately $560 million by 2030. Opportunities exist in developing thermostable formulations, simplifying vaccination schedules, and expanding access through generic manufacturing.

Key Takeaways

• The rabies vaccine market is expanding modestly, with significant growth potential in Asia-Pacific and Africa.
• Pfizer's RabAvert remains the leading product, with ongoing pipeline development focused on improving efficacy and cost.
• Public health policies and awareness campaigns significantly impact market growth.

FAQs

1. What are the primary drivers for rabies vaccine market growth?
Increasing awareness, expanding immunization programs, and a rising dog population in developing countries.

2. Who are the dominant players?
Pfizer, GSK, and Merck dominate, with Pfizer holding about half the market share.

3. How do regulatory policies influence market dynamics?
Regulations direct approval timelines, pricing, and distribution; WHO guidelines standardize best practices.

4. What are the main barriers to market expansion?
High vaccine costs in low-income regions, cold chain logistics, and vaccine hesitancy.

5. What innovations are shaping future market developments?
Thermostable formulations, reduced dose schedules, and recombinant or adjuvant technologies.

Citations

[1] MarketsandMarkets, "Rabies Vaccine Market," 2023
[2] WHO, "Rabies Fact Sheet," 2022
[3] Pfizer, "Rabies Vaccine Portfolio," 2023
[4] GSK, "Innovations in Rabies Vaccines," 2022
[5] Statista, "Global Rabies Vaccine Revenue," 2023